Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors

Singh S., Gleason CE., Fang M., Laimon YN., Khivansara V., Xie S., Durmaz YT., Sarkar A., Ngo K., Savla V., Li Y., Abu-Remaileh M., Li X., Locquet M-A., Tuladhar B., Odeh R., Hamkins-Indik F., He D., Membreno MW., Nosrati M., Gushwa NN., Leung SSF., Fraga-Walton B., Hernandez L., Baldomero MP., Lent BM., Spellmeyer D., Luna JF., Hoang D., Gritsenko Y., Chand M., DeMart MK., Metobo S., Bhatt C., Shapiro JA., Yang K., Dupper NJ., Bockus AT., Fang J., Bambal R., Cremin P., Doench JG., Aggen JB., Liu L-F., Levin B., Wang EW., Vendrell I., Fischer R., Kessler B., Gokhale PC., Signoretti S., Spektor A., Kreatsoulas C., Evangelista M., Singh R., Earp DJ., Nijhawan D., Garcia PD., Oser MG.

DOI

10.1038/s41586-025-09433-w

Type

Journal article

Publisher

Springer Science and Business Media LLC

Publication Date

2025-10-16T00:00:00+00:00

Volume

646

Pages

734 - 745

Total pages

11

Permalink More information Close